Pub Date : 2024-10-01Epub Date: 2024-06-03DOI: 10.1007/s00115-024-01682-w
Jens Schaumberg
{"title":"[Migraine or pseudomigraine, that is the question! : The HaNDL syndrome].","authors":"Jens Schaumberg","doi":"10.1007/s00115-024-01682-w","DOIUrl":"10.1007/s00115-024-01682-w","url":null,"abstract":"","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"938-941"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1007/s00115-024-01748-9
{"title":"Mitteilungen der Deutschen Schlaganfall-Gesellschaft (DSG).","authors":"","doi":"10.1007/s00115-024-01748-9","DOIUrl":"10.1007/s00115-024-01748-9","url":null,"abstract":"","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":"95 10","pages":"974-976"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-12DOI: 10.1007/s00115-024-01743-0
B Bassa, F Hahner, U Meyding-Lamadé
Pathogen-induced myelitis is an inflammatory disease of the spinal cord that can be caused by various pathogens including viruses, bacteria, fungi or parasites. The most frequent viral pathogens include herpes and enteroviruses, while bacterial myelitis can be caused by, e.g., Mycobacterium tuberculosis, Borrelia burgdorferi and Treponema pallidum. Fungi such as Candida and Aspergillus and parasites such as Toxoplasma gondii and schistosomes can also cause myelitis. The main symptom is subacute paraplegia with motor, sensory and autonomic deficits to varying degrees, often accompanied by fever and a general malaise. Following a thorough clinical examination and review of the medical history diagnostic imaging procedures, such as magnetic resonance imaging (MRI) along with cerebrospinal fluid analysis and blood tests that include antibody testing are warranted. The treatment is directed at the cause of the myelitis and mostly with anti-infective agents but for some viral pathogens no specific treatment is available and the only option is a symptomatic treatment. The prognosis is very variable and depends on the etiology and severity of the disease. A fast diagnosis and targeted treatment are crucial to achieve a good outcome.
{"title":"[Pathogen-induced diseases of the spinal cord and adjacent structures].","authors":"B Bassa, F Hahner, U Meyding-Lamadé","doi":"10.1007/s00115-024-01743-0","DOIUrl":"10.1007/s00115-024-01743-0","url":null,"abstract":"<p><p>Pathogen-induced myelitis is an inflammatory disease of the spinal cord that can be caused by various pathogens including viruses, bacteria, fungi or parasites. The most frequent viral pathogens include herpes and enteroviruses, while bacterial myelitis can be caused by, e.g., Mycobacterium tuberculosis, Borrelia burgdorferi and Treponema pallidum. Fungi such as Candida and Aspergillus and parasites such as Toxoplasma gondii and schistosomes can also cause myelitis. The main symptom is subacute paraplegia with motor, sensory and autonomic deficits to varying degrees, often accompanied by fever and a general malaise. Following a thorough clinical examination and review of the medical history diagnostic imaging procedures, such as magnetic resonance imaging (MRI) along with cerebrospinal fluid analysis and blood tests that include antibody testing are warranted. The treatment is directed at the cause of the myelitis and mostly with anti-infective agents but for some viral pathogens no specific treatment is available and the only option is a symptomatic treatment. The prognosis is very variable and depends on the etiology and severity of the disease. A fast diagnosis and targeted treatment are crucial to achieve a good outcome.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"948-956"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-09-20DOI: 10.1007/s00115-024-01725-2
Sarah Hoffmann, Marie-Therese Holzer, Corinna Preuße, Tobias Ruck, Nikolas Ruffer, Frauke Stascheit, Werner Stenzel
This article deals with peripheral neuroimmunological diseases and briefly outlines the currently most important aspects and treatment developments. Idiopathic inflammatory myopathies have different mechanisms of development, manifestations and prognoses. New classification systems and more specific treatment concepts have been developed. The IIMs include different subgroups. These entities can have specific autoantibodies. Diagnostically, a muscle biopsy is generally desirable for a precise diagnosis and is essential in unclear cases. Primary systemic vasculitides can be divided into different groups based on the predominant pattern of involvement, while secondary vasculitides and single organ vasculitides are also differentiated. Vasculitic myopathy cannot be equated with myositis and a reliable distinction is currently only possible by a muscle biopsy. Treatment concepts should be developed on an interdisciplinary basis. Chronic inflammatory demyelinating polyneuropathy is the most frequent immune-mediated neuropathy and is characterized by a predominant demyelination of the motor and sensory nerves. The disease course runs in phases or is progressive and leads to significant disability and reduction in quality of life, despite current standard treatment. Novel treatment approaches are currently undergoing clinical trials. Myasthenia gravis, with the leading symptom of exercise-induced muscle weakness, is caused by autoantibodies against structures of the neuromuscular endplate. Autoantibody testing is the most important pillar in the diagnosis and is now also increasingly guiding treatment decisions. Overall, peripheral neuroimmunological diseases represent a heterogeneous group. Increasing knowledge of the pathophysiology is the key to numerous developments in diagnostics and treatment, which could lead to far-reaching practical changes in the future.
{"title":"[Peripheral neuroimmunological diseases - Neuropathological insights and clinical perspectives].","authors":"Sarah Hoffmann, Marie-Therese Holzer, Corinna Preuße, Tobias Ruck, Nikolas Ruffer, Frauke Stascheit, Werner Stenzel","doi":"10.1007/s00115-024-01725-2","DOIUrl":"10.1007/s00115-024-01725-2","url":null,"abstract":"<p><p>This article deals with peripheral neuroimmunological diseases and briefly outlines the currently most important aspects and treatment developments. Idiopathic inflammatory myopathies have different mechanisms of development, manifestations and prognoses. New classification systems and more specific treatment concepts have been developed. The IIMs include different subgroups. These entities can have specific autoantibodies. Diagnostically, a muscle biopsy is generally desirable for a precise diagnosis and is essential in unclear cases. Primary systemic vasculitides can be divided into different groups based on the predominant pattern of involvement, while secondary vasculitides and single organ vasculitides are also differentiated. Vasculitic myopathy cannot be equated with myositis and a reliable distinction is currently only possible by a muscle biopsy. Treatment concepts should be developed on an interdisciplinary basis. Chronic inflammatory demyelinating polyneuropathy is the most frequent immune-mediated neuropathy and is characterized by a predominant demyelination of the motor and sensory nerves. The disease course runs in phases or is progressive and leads to significant disability and reduction in quality of life, despite current standard treatment. Novel treatment approaches are currently undergoing clinical trials. Myasthenia gravis, with the leading symptom of exercise-induced muscle weakness, is caused by autoantibodies against structures of the neuromuscular endplate. Autoantibody testing is the most important pillar in the diagnosis and is now also increasingly guiding treatment decisions. Overall, peripheral neuroimmunological diseases represent a heterogeneous group. Increasing knowledge of the pathophysiology is the key to numerous developments in diagnostics and treatment, which could lead to far-reaching practical changes in the future.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"920-931"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01Epub Date: 2024-07-02DOI: 10.1007/s00115-024-01696-4
Hansjörg Schild, Tobias Bopp
Background: Neurodegenerative diseases represent an increasing challenge in ageing societies, as only limited treatment options are currently available.
Objective: New research methods and interdisciplinary interaction of different disciplines have changed the way neurological disorders are viewed and paved the way for the comparatively new field of neuroimmunology, which was established in the early 1980s. Starting from neurological autoimmune diseases, such as multiple sclerosis, knowledge about the involvement of immunological processes in other contexts, such as stroke or traumatic brain injury, has been significantly expanded in recent years.
Material and methods: This review article provides an overview of the role of the immune system and the resulting potential for novel treatment approaches.
Results: The immune system plays a central role in fighting infections but is also able to react to the body's own signals under sterile conditions and cause inflammation and subsequent adaptive immune responses through the release of immune mediators and the recruitment and differentiation of certain immune cell types. This can be beneficial in initiating healing processes; however, chronic inflammatory conditions usually have destructive consequences for the tissue and the organism and must be interrupted.
Conclusion: It is now known that different cells of the immune system play an important role in neurological diseases. Regulatory mechanisms, which are mediated by regulatory T cells or Th2 cells, are usually associated with a good prognosis, whereas inflammatory processes and polarization towards Th1 or Th17 have a destructive character. Novel immunomodulators, which are also increasingly being used in cancer treatment, can now be used in a tissue-specific manner and therefore offer great potential for use in neurological diseases.
{"title":"[Immunological foundations of neurological diseases].","authors":"Hansjörg Schild, Tobias Bopp","doi":"10.1007/s00115-024-01696-4","DOIUrl":"10.1007/s00115-024-01696-4","url":null,"abstract":"<p><strong>Background: </strong>Neurodegenerative diseases represent an increasing challenge in ageing societies, as only limited treatment options are currently available.</p><p><strong>Objective: </strong>New research methods and interdisciplinary interaction of different disciplines have changed the way neurological disorders are viewed and paved the way for the comparatively new field of neuroimmunology, which was established in the early 1980s. Starting from neurological autoimmune diseases, such as multiple sclerosis, knowledge about the involvement of immunological processes in other contexts, such as stroke or traumatic brain injury, has been significantly expanded in recent years.</p><p><strong>Material and methods: </strong>This review article provides an overview of the role of the immune system and the resulting potential for novel treatment approaches.</p><p><strong>Results: </strong>The immune system plays a central role in fighting infections but is also able to react to the body's own signals under sterile conditions and cause inflammation and subsequent adaptive immune responses through the release of immune mediators and the recruitment and differentiation of certain immune cell types. This can be beneficial in initiating healing processes; however, chronic inflammatory conditions usually have destructive consequences for the tissue and the organism and must be interrupted.</p><p><strong>Conclusion: </strong>It is now known that different cells of the immune system play an important role in neurological diseases. Regulatory mechanisms, which are mediated by regulatory T cells or Th2 cells, are usually associated with a good prognosis, whereas inflammatory processes and polarization towards Th1 or Th17 have a destructive character. Novel immunomodulators, which are also increasingly being used in cancer treatment, can now be used in a tissue-specific manner and therefore offer great potential for use in neurological diseases.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"894-908"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-26DOI: 10.1007/s00115-024-01745-y
Beatrice Rose, Jörg-Stefan Schulz, Eckhard Sundermann, Paraskevi Mavrogiorgou, Georg Juckel
Background: Even 90 years after the National Socialist seizure of power and the beginning of the darkest chapter of German psychiatric history, examination of the medical historical past retains great relevance as an ongoing medical responsibility. The interventions in the lives of mentally ill people by the National Socialist regime are a firmly established part of medical historical research; however, little is known about how specific regions proceeded with affected citizens.
Objective: The aim of this study was therefore to identify transfer routes of the "euthanasia" transports and places of death of the victims from Bochum as well as their patient characteristics.
Materials and methods: During the timeframe studied, inpatient care for mentally ill patients from the Westphalia region was provided in seven provincial institutions. There was no psychiatric clinic in Bochum at the time, so patients were distributed among these institutions. The investigation was based on the transfer lists of the Westphalian provincial institutions to the killing sites.
Results and conclusion: A total of 366 Bochum citizens affected by "euthanasia" transfers were identified. The transport lists were verified by admission and departure books, death lists, and patient files. The hereditary health files of the city archive were used to examine the relocated Bochum patients to determine whether they were victims of forced sterilization.
{"title":"[Mentally ill citizens as victims of violation of physical integrity and extermination under the NS regime based on the example of a German city].","authors":"Beatrice Rose, Jörg-Stefan Schulz, Eckhard Sundermann, Paraskevi Mavrogiorgou, Georg Juckel","doi":"10.1007/s00115-024-01745-y","DOIUrl":"https://doi.org/10.1007/s00115-024-01745-y","url":null,"abstract":"<p><strong>Background: </strong>Even 90 years after the National Socialist seizure of power and the beginning of the darkest chapter of German psychiatric history, examination of the medical historical past retains great relevance as an ongoing medical responsibility. The interventions in the lives of mentally ill people by the National Socialist regime are a firmly established part of medical historical research; however, little is known about how specific regions proceeded with affected citizens.</p><p><strong>Objective: </strong>The aim of this study was therefore to identify transfer routes of the \"euthanasia\" transports and places of death of the victims from Bochum as well as their patient characteristics.</p><p><strong>Materials and methods: </strong>During the timeframe studied, inpatient care for mentally ill patients from the Westphalia region was provided in seven provincial institutions. There was no psychiatric clinic in Bochum at the time, so patients were distributed among these institutions. The investigation was based on the transfer lists of the Westphalian provincial institutions to the killing sites.</p><p><strong>Results and conclusion: </strong>A total of 366 Bochum citizens affected by \"euthanasia\" transfers were identified. The transport lists were verified by admission and departure books, death lists, and patient files. The hereditary health files of the city archive were used to examine the relocated Bochum patients to determine whether they were victims of forced sterilization.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-24DOI: 10.1007/s00115-024-01737-y
Laura L Kilarski, Isabelle Claus, Elisabeth B Binder, Franziska Degenhardt, Katharina Domschke, Andreas J Forstner, Hans J Grabe, Urs Heilbronner, Daniel Müller, Markus M Nöthen, Franziska Radtke, Marcella Rietschel, Thomas G Schulze, Fabian Streit, Ludger Tebartz van Elst, Oliver Tüscher, Jürgen Deckert, Eva C Schulte
This review article provides insights into the role of genetic diagnostics in adult mental health disorders. The importance of genetic factors in the development of mental illnesses, from rare genetic syndromes to common complex genetic disorders, is described. Current clinical characteristics that may warrant a genetic diagnostic work-up are highlighted, including intellectual disability, autism spectrum disorders and severe psychiatric conditions with specific comorbidities, such as organ malformations or epilepsy. The review discusses when genetic diagnostics are recommended according to current guidelines as well as situations where they might be considered even in the absence of explicit guideline recommendations. This is followed by an overview of the procedures and the currently used diagnostic methods. Current limitations and possible developments in the field of genetic diagnostics in psychiatry are discussed, including the fact that, for many mental health conditions, genetic testing is not yet part of standard clinical practice; however, in summary genetic causes should be considered more frequently in certain clinical constellations, and genetic diagnostics and counselling should be offered where appropriate.
{"title":"[Genetic diagnostics of mental health disorders in adulthood].","authors":"Laura L Kilarski, Isabelle Claus, Elisabeth B Binder, Franziska Degenhardt, Katharina Domschke, Andreas J Forstner, Hans J Grabe, Urs Heilbronner, Daniel Müller, Markus M Nöthen, Franziska Radtke, Marcella Rietschel, Thomas G Schulze, Fabian Streit, Ludger Tebartz van Elst, Oliver Tüscher, Jürgen Deckert, Eva C Schulte","doi":"10.1007/s00115-024-01737-y","DOIUrl":"https://doi.org/10.1007/s00115-024-01737-y","url":null,"abstract":"<p><p>This review article provides insights into the role of genetic diagnostics in adult mental health disorders. The importance of genetic factors in the development of mental illnesses, from rare genetic syndromes to common complex genetic disorders, is described. Current clinical characteristics that may warrant a genetic diagnostic work-up are highlighted, including intellectual disability, autism spectrum disorders and severe psychiatric conditions with specific comorbidities, such as organ malformations or epilepsy. The review discusses when genetic diagnostics are recommended according to current guidelines as well as situations where they might be considered even in the absence of explicit guideline recommendations. This is followed by an overview of the procedures and the currently used diagnostic methods. Current limitations and possible developments in the field of genetic diagnostics in psychiatry are discussed, including the fact that, for many mental health conditions, genetic testing is not yet part of standard clinical practice; however, in summary genetic causes should be considered more frequently in certain clinical constellations, and genetic diagnostics and counselling should be offered where appropriate.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-23DOI: 10.1007/s00115-024-01736-z
Dominik Diesing, Peter Neu
Objective: The increasing popularity of nitrous oxide (N2O) as a recreational drug raises questions about its potential for dependency. This narrative review examines the dependency risk of N2O using the ICD-10 criteria for substance use disorders and evaluates the current literature.
Material and methods: A comprehensive literature search until April 2024 was conducted to identify publications addressing N2O consumption in the context of dependency criteria. The results were analyzed based on the ICD-10 criteria.
Results: Studies showed mixed results regarding craving and loss of control among N2O users. There is evidence of neglect of other interests and potential tolerance development, while data on withdrawal symptoms are limited. Persistent consumption despite harmful consequences has been described but objective diagnostic methods to determine consumption intensity are lacking.
Discussion: The data on the dependency potential of N2O are inconsistent. The discussion on its classification as an addictive substance remains controversial; however, the clinical indications suggest a possible risk of dependency, especially with excessive consumption.
Conclusion: Nitrous oxide is currently primarily regarded as a substance of abuse with the potential to foster psychological dependence, manifesting particularly through loss of control and neglect; however, the criteria for physical dependence, such as the occurrence of withdrawal syndromes and the development of tolerance, have not yet been convincingly documented. Further research is needed to better understand the dependency potential of N2O and develop appropriate preventive and therapeutic measures.
{"title":"[Life style drug laughing gas (nitrous oxide, N<sub>2</sub>O) and the dependency criteria according to ICD-10].","authors":"Dominik Diesing, Peter Neu","doi":"10.1007/s00115-024-01736-z","DOIUrl":"https://doi.org/10.1007/s00115-024-01736-z","url":null,"abstract":"<p><strong>Objective: </strong>The increasing popularity of nitrous oxide (N<sub>2</sub>O) as a recreational drug raises questions about its potential for dependency. This narrative review examines the dependency risk of N<sub>2</sub>O using the ICD-10 criteria for substance use disorders and evaluates the current literature.</p><p><strong>Material and methods: </strong>A comprehensive literature search until April 2024 was conducted to identify publications addressing N<sub>2</sub>O consumption in the context of dependency criteria. The results were analyzed based on the ICD-10 criteria.</p><p><strong>Results: </strong>Studies showed mixed results regarding craving and loss of control among N<sub>2</sub>O users. There is evidence of neglect of other interests and potential tolerance development, while data on withdrawal symptoms are limited. Persistent consumption despite harmful consequences has been described but objective diagnostic methods to determine consumption intensity are lacking.</p><p><strong>Discussion: </strong>The data on the dependency potential of N<sub>2</sub>O are inconsistent. The discussion on its classification as an addictive substance remains controversial; however, the clinical indications suggest a possible risk of dependency, especially with excessive consumption.</p><p><strong>Conclusion: </strong>Nitrous oxide is currently primarily regarded as a substance of abuse with the potential to foster psychological dependence, manifesting particularly through loss of control and neglect; however, the criteria for physical dependence, such as the occurrence of withdrawal syndromes and the development of tolerance, have not yet been convincingly documented. Further research is needed to better understand the dependency potential of N<sub>2</sub>O and develop appropriate preventive and therapeutic measures.</p>","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1007/s00115-024-01733-2
Wolfgang Strube, Elias Wagner, Andreas Gartenmaier, Antje Grünemeyer, Klaus Peter Schmelzer, Alkomiet Hasan
{"title":"[Risk for post-injection syndrome after administration of olanzapine depot : Findings of real-world data evaluation at a psychiatric university hospital with a full-range care mandate].","authors":"Wolfgang Strube, Elias Wagner, Andreas Gartenmaier, Antje Grünemeyer, Klaus Peter Schmelzer, Alkomiet Hasan","doi":"10.1007/s00115-024-01733-2","DOIUrl":"10.1007/s00115-024-01733-2","url":null,"abstract":"","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}